Elutia (ELUT) Return on Capital Employed (2020 - 2026)
Elutia (ELUT) reported Return on Capital Employed of 79.85% for Q1 2026, up 362531.0% on a YoY basis from N/an in Q1 2025, and up 41.73% sequentially from 137.04% in Q4 2025.
Elutia (ELUT) Return on Capital Employed (2020 - 2026) Analysis & Trends
Elutia (ELUT) has 7 years of Return on Capital Employed data on file, last reported at 79.85% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 362531.0% year-over-year to 79.85%; the trailing twelve-month figure through Mar 2026 stood at 79.85% (up 362531.0% YoY), and the FY2025 full-year result was 111.67%, up 143749.0% from the prior year.
- Return on Capital Employed improved to 79.85% in Q1 2026, from 137.04% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2797.28% in Q2 2024 to a low of 3705.17% in Q1 2025.
- A 5-year average of 230.18% and a median of 150.55% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 215906 bps in 2024 and jumped 362531 bps in 2026, its largest moves.
- Tracing ELUT's Return on Capital Employed over 5 years: stood at 150.55% in 2022, then tumbled by 240 bps to 511.6% in 2023, then tumbled by 47 bps to 751.83% in 2024, then soared by 82 bps to 137.04% in 2025, then jumped by 42 bps to 79.85% in 2026.
- Business Quant data shows ELUT's Return on Capital Employed at 79.85% in Q1 2026, 137.04% in Q4 2025, and 302.06% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Elutia | 39.99 Mn | 11.50 Mn | 1.80 Mn | -79.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.85% |
| Dec 31, 2025 | -137.04% |
| Sep 30, 2025 | 302.06% |
| Jun 30, 2025 | 2,421.61% |
| Mar 31, 2025 | -3,705.17% |
| Dec 31, 2024 | -751.83% |
| Sep 30, 2024 | -632.99% |
| Jun 30, 2024 | 2,797.28% |
| Mar 31, 2024 | -2,309.26% |
| Dec 31, 2023 | -511.60% |
| Sep 30, 2023 | -361.83% |
| Jun 30, 2023 | -243.47% |
| Mar 31, 2023 | -150.20% |
| Dec 31, 2022 | -150.55% |
| Sep 30, 2022 | -189.82% |
| Jun 30, 2022 | -137.90% |
| Mar 31, 2022 | -72.47% |
| Dec 31, 2021 | -61.36% |
| Sep 30, 2021 | -45.48% |
| Jun 30, 2021 | -30.91% |